PARIS--(BUSINESS WIRE)--Cytheris SA, a product-oriented biopharmaceutical company focused on research and development of new and critical agents for immune-modulation, today announced that Richard W. Keatinge, Ph.D., has joined the Company in the newly created position of Chief Business Officer, reporting to Michel Morre, DVM, President and Chief Executive Officer. Prior to joining Cytheris, Dr. Keatinge was a Managing Director and Vice President of Business Development at BioAlliance Pharma SA, Paris (Euronext:BIO), where he played a key role in the company’s initial public offering on NYSE Euronext.
